Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients.

BACKGROUND: It is well known that some circulating microRNAs (miRNAs) are highly stable and might serve as promising biomarkers for many types of human cancer including glioblastoma (GBM). However, the potential clinical significance of serum miR-100 in GBM remained unknown.

OBJECTIVE: We aimed to detect the expression level of serum miR-100 in patients with GBM and assess its potential diagnostic and prognostic value.

METHODS: Quantitative real-time PCR was performed to measure serum miR-100 levels in 95 GBM patients and 60 healthy volunteers. The association between serum miR-100 level and clinicopathological parameters as well survival of GBM patients was evaluated.

RESULTS: Our results revealed that serum miR-100 levels were significantly decreased in GBM patients compared with the healthy controls. Additionally, miR-100 levels were significantly elevated after treatment. Low miR-100 expression was closely correlated with worse clinicopathological characteristics. Further receiver operating characteristic (ROC) curve analysis showed that serum miR-100 could effectively discriminate GBM cases from normal controls. Moreover, survival analyses revealed that patients with high serum miR-100 levels had significantly longer survival time than those with low serum miR-100 levels. Finally, multivariate analysis identified serum miR-100 as an independent prognostic indicator for GBM.

CONCLUSIONS: Our findings suggested that serum miR-100 might serve as promising biomarker for GBM diagnosis and prognosis.